Lydie Meheus is Managing Director of the Anticancer Fund (ACF), a Belgian Research Foundation of Public Utility with an international scope, dedicated to the development of cancer treatments regardless of their commercial value. The Anticancer Fund invests in cancer research, helps cancer patients by giving reliable information on treatment options and engages with decisionmakers to eliminate barriers to more and affordable cancer treatments.
Lydie co-founded the Anticancer Fund in 2013 with entrepreneur and major funder Luc Verelst, after leading an alike Swiss organisation, Reliable Cancer Therapies, also initiated in 2009 by Luc Verelst. Lydie is still Executive Director of Reliable Cancer Therapies, today the collaborating partner outside Europe of the Anticancer Fund.
Lydie is a breast cancer patient, diagnosed in 2018 and successfully treated since then.
In 2019, Lydie was appointed by the European Commission as alternate to represent patients for 3 years in the Committee for Advanced Therapies (CAT). The CAT, one of the seven committees at the European Medicines Agency (EMA), is responsible for assessing the quality, safety and efficacy of advanced-therapy medicinal products (ATMP’s) and for following scientific developments in the field.
Lydie is also member of the Scientific and Clinical Advisory Board of OvaCure, a Danish non-profit organisation that supports research for breakthrough treatments, ultimately leading to a cure for ovarian cancer. She launched OvaCure together with the founder Juliane Meulengracht Bang.
She has published many international peer review manuscripts and book chapters, especially on drug repurposing in cancer therapies.
She obtained a PhD in Sciences at the University of Ghent (1986). She worked at Innogenetics (1987-2004) and as VP R&D at GENimmune (2005-2008), both Belgian biopharmaceutical companies.
Updated: September 2020